How newer medicines for chronic lymphocytic leukemia work over time
Outcomes for CLL patients treated with novel therapy
This project looks at how well frontline ibrutinib-based therapy (ibrutinib plus rituximab) holds up over time for people with newly diagnosed chronic lymphocytic leukemia (CLL).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11182706 on NIH RePORTER |
What this research studies
Researchers previously ran a large North American trial showing ibrutinib plus rituximab improved survival compared with older chemoimmunotherapy. They plan to combine clinical information, tumor tests, and advanced lab assays (including analyses like ATAC-seq) to build models that predict how long a patient will stay in remission on ibrutinib-based treatment. The goal is to tell who might do well with time-limited therapy versus who may need more intensive or alternative approaches. If you have CLL and provided clinical data or tumor samples to this effort, your information could help refine those predictions.
Who could benefit from this research
Good fit: Ideal candidates are adults with newly diagnosed, previously untreated CLL who received or are receiving frontline ibrutinib-based therapy and can share clinical records and tumor samples.
Not a fit: People without CLL or those not treated with frontline ibrutinib-based regimens are unlikely to be eligible or to gain direct benefit from this project.
Why it matters
Potential benefit: Could help doctors personalize CLL care by identifying patients who can safely stop ibrutinib-based therapy and those who need different or intensified treatment.
How similar studies have performed: A prior phase 3 trial (E1912) already showed clinical benefit of ibrutinib plus rituximab over older chemo, while using biomarkers and chromatin assays to predict long-term durability is a newer approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kay, Neil E — Mayo Clinic Rochester
- Study coordinator: Kay, Neil E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.